PL2276483T3 - Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania - Google Patents

Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania

Info

Publication number
PL2276483T3
PL2276483T3 PL08742326T PL08742326T PL2276483T3 PL 2276483 T3 PL2276483 T3 PL 2276483T3 PL 08742326 T PL08742326 T PL 08742326T PL 08742326 T PL08742326 T PL 08742326T PL 2276483 T3 PL2276483 T3 PL 2276483T3
Authority
PL
Poland
Prior art keywords
acetylaminoisoindoline
methylsulfonylethyl
dione
methoxyphenyl
ethoxy
Prior art date
Application number
PL08742326T
Other languages
English (en)
Inventor
George W Muller
Peter H Schafer
Hon-Wah Man
Chuansheng Ge
Jean Xu
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40043076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2276483(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PL2276483T3 publication Critical patent/PL2276483T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
PL08742326T 2008-03-27 2008-03-27 Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania PL2276483T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2008/004021 WO2009120167A1 (en) 2008-03-27 2008-03-27 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP08742326.5A EP2276483B1 (en) 2008-03-27 2008-03-27 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof

Publications (1)

Publication Number Publication Date
PL2276483T3 true PL2276483T3 (pl) 2014-09-30

Family

ID=40043076

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08742326T PL2276483T3 (pl) 2008-03-27 2008-03-27 Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania

Country Status (21)

Country Link
EP (2) EP2276483B1 (pl)
JP (1) JP5474043B2 (pl)
KR (3) KR20140142323A (pl)
CN (1) CN102046167A (pl)
AU (1) AU2008353468B2 (pl)
BR (1) BRPI0822398B8 (pl)
CA (1) CA2718601A1 (pl)
CY (1) CY1115361T1 (pl)
DK (1) DK2276483T3 (pl)
ES (1) ES2476252T3 (pl)
HR (1) HRP20140609T1 (pl)
IL (3) IL208216A0 (pl)
MX (2) MX2010010454A (pl)
NO (1) NO2015017I1 (pl)
NZ (1) NZ588104A (pl)
PL (1) PL2276483T3 (pl)
PT (1) PT2276483E (pl)
RU (1) RU2471782C2 (pl)
SI (1) SI2276483T1 (pl)
WO (1) WO2009120167A1 (pl)
ZA (1) ZA201006663B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
KR101514866B1 (ko) 2009-05-14 2015-04-24 티안진 헤메이 바이오-텍 컴퍼니 리미티드 티오펜 유도체
MX2012004741A (es) * 2009-11-19 2012-05-22 Celgene Corp Apremilast para el tratamiento de sarcoidosis.
JP2013531499A (ja) * 2010-06-15 2013-08-08 セルジーン コーポレイション 乾癬の治療のためのバイオマーカー
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
MX354210B (es) * 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
AU2012362562B2 (en) * 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP2730278A1 (en) * 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
EP2916869A1 (en) * 2012-11-09 2015-09-16 Celgene Corporation Methods for the treatment of bone loss
JP2014114308A (ja) * 2014-01-31 2014-06-26 Celgene Corp （＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオンを含む固形物形態、その組成物およびその使用
IN2014MU01283A (pl) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
WO2015200177A1 (en) * 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN105294534B (zh) * 2014-07-15 2020-04-10 上海优拓医药科技有限公司 制备阿普司特及其中间体的产业化方法
CN104761484B (zh) 2014-11-24 2018-03-27 上海优拓医药科技有限公司 一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法
CN104496886A (zh) * 2014-12-11 2015-04-08 杭州新博思生物医药有限公司 一种高纯度阿普斯特b晶型的制备方法
EP3034496A1 (en) * 2014-12-18 2016-06-22 LEK Pharmaceuticals d.d. Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide
WO2016135755A1 (en) 2015-02-27 2016-09-01 Mylan Laboratories Limited Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
EP3271330A1 (en) 2015-03-19 2018-01-24 Cipla Limited Improved process for the preparation of apremilast
WO2016169533A1 (en) 2015-04-24 2016-10-27 Zentiva, K.S. A solid form of apremilast and a process for preparing the same
CN104892486B (zh) * 2015-06-25 2017-12-08 济南纽华医药科技有限公司 阿普斯特的晶型b+及其制备方法
US10544097B2 (en) 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
US9765026B2 (en) 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
CN105218428A (zh) * 2015-10-20 2016-01-06 南京美嘉宁逸医药研究开发有限公司 一种高手性纯度的阿普斯特的制备方法
WO2017076987A1 (en) * 2015-11-03 2017-05-11 Ratiopharm Gmbh Composition comprising apremilast in amorphous form
CN105330587A (zh) * 2015-11-27 2016-02-17 东华大学 一种3-乙酰胺基邻苯二甲酰亚胺的制备方法
CZ20165A3 (cs) 2016-01-06 2017-07-19 Zentiva, K.S. Způsoby přípravy amorfního apremilastu
US10774042B2 (en) * 2016-05-12 2020-09-15 Zaklady Farmaceutyczne Polpharma Sa Crystalline forms of apremilast
WO2017216738A1 (en) 2016-06-15 2017-12-21 Torrent Pharmaceuticals Limited Topical compositions of apremilast
CN106008315A (zh) * 2016-06-16 2016-10-12 珠海联邦制药股份有限公司 一种阿普斯特晶型s及其制备方法
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN107686461A (zh) * 2016-08-04 2018-02-13 广东东阳光药业有限公司 阿普斯特的溶剂化物及其制备方法和用途
CN110049968A (zh) * 2016-11-09 2019-07-23 广东东阳光药业有限公司 阿普斯特共晶及其制备方法
EP3339292A1 (en) 2016-12-23 2018-06-27 Zaklady Farmaceutyczne Polpharma SA Cocrystals of apremilast
US11337964B2 (en) * 2017-02-28 2022-05-24 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, pharmaceutical composition and use thereof
AU2019229583B2 (en) 2018-03-07 2024-06-13 Amgen (Europe) GmbH Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases
EP3929179A1 (en) 2020-06-22 2021-12-29 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
CN115068467A (zh) * 2021-03-15 2022-09-20 中国医学科学院药物研究所 穿心莲内酯作为ltb4受体抑制剂的医药用途
US12351555B2 (en) 2021-04-26 2025-07-08 Amgen Inc. Process for synthesizing apremilast
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023118043A1 (en) 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf

Also Published As

Publication number Publication date
AU2008353468B2 (en) 2015-08-06
ZA201006663B (en) 2012-02-29
RU2471782C2 (ru) 2013-01-10
HRP20140609T1 (hr) 2014-08-15
MX359839B (es) 2018-10-12
CY1115361T1 (el) 2017-01-04
IL227991A0 (en) 2013-09-30
PT2276483E (pt) 2014-07-25
KR20150038547A (ko) 2015-04-08
MX2010010454A (es) 2010-12-20
EP2276483A1 (en) 2011-01-26
NZ588104A (en) 2012-11-30
KR20140142323A (ko) 2014-12-11
BRPI0822398B8 (pt) 2018-05-29
IL208216A0 (en) 2010-12-30
JP2011515463A (ja) 2011-05-19
WO2009120167A1 (en) 2009-10-01
EP2276483B1 (en) 2014-05-07
DK2276483T3 (da) 2014-06-10
IL247411A0 (en) 2016-11-30
BRPI0822398A2 (pt) 2014-11-18
ES2476252T3 (es) 2014-07-14
SI2276483T1 (sl) 2014-08-29
CA2718601A1 (en) 2009-10-01
KR20100132045A (ko) 2010-12-16
RU2010143907A (ru) 2012-05-10
EP2695616A1 (en) 2014-02-12
JP5474043B2 (ja) 2014-04-16
AU2008353468A1 (en) 2009-10-01
BRPI0822398B1 (pt) 2018-01-16
CN102046167A (zh) 2011-05-04
NO2015017I1 (no) 2015-07-27

Similar Documents

Publication Publication Date Title
IL247411A0 (en) Solid forms containing (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoinsulin-1,3-dione, their preparations containing them and their uses
IL242192A (en) Certain chemicals, preparations and methods
IL248652A0 (en) Methods, compositions and devices for facilitating re-creation
IL220009A0 (en) Indole compounds, compositions comprising the same and uses thereof
EP2195328A4 (en) PARTICULAR CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
EP2139478A4 (en) CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
PT2362866E (pt) Compostos de isoprenila e métodos dos mesmos
IL215051A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
ZA201005780B (en) Certain chemical entities,compositions and methods
IL215050A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL215049A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
PL2313178T3 (pl) Kompozycje redukujące aldehyd
ZA201000138B (en) Compositions and methods for reducing stool volume and stool odor
GB0719367D0 (en) Transcription factor decoys, compositions and methods
PL2323634T3 (pl) Kompozycja ropinirolu
IL209718A0 (en) Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof
ZA200907150B (en) New compositions and methods for cell killing
ZA201101520B (en) Phenanthrenone compounds,compositions and methods
HK1149204A (en) Certain chemical entities, compositions and methods
HK1162357A (en) Compositions and methods for improved oral health
HK1147959A (en) Cleaning compositions and methods
EP2040890A4 (en) ENTSAFTUNGSMESSER
PL383212A1 (pl) Nowa DD-karboksypeptydaza, jej otrzymywanie i zastosowania
IL194260A (en) Methods and Components for Exterminating Parasites